动物实验显示低剂量 semaglutide 或可独立于减重减轻射血分数保留心衰的心脏僵硬
Weight loss drugs may protect against heart failure
Cedars-Sinai 团队给模拟肥胖相关射血分数保留心衰的大鼠和小型猪使用低剂量 semaglutide,发现其未减少体重却显著减轻心脏僵硬,还观察到心脏增大与组织瘢痕减少,心脏和肝脏周围有害脂肪被清除。研究刊于 European Heart Journal,作者认为这为低剂量 GLP-1 药物独立于减重提供心血管保护提供了机理依据。
Weight-loss drugs known as GLP-1s may help protect against heart failure even at doses too low to produce significant weight loss, according to a laboratory study led by Cedars-Sinai Health Sciences University investigators.
"Our findings provide a strong mechanistic rationale for studying GLP-1 medicines as potential treatments for heart failure," said David Lefer, Ph.D., director of translational research in the Department of Cardiac Surgery in the Smidt Heart Institute at Cedars-Sinai.
The study, published in the European Heart Journal, investigated the drugs' effects on heart failure with preserved ejection fraction. The incurable disorder, in which the heart pumps out blood normally but is too stiff to fill properly, accounts for more than half of the roughly 6.7 million heart failure cases in the U.S. each year, according to the American College of Cardiology.
Investigators administered low doses of semaglutide, a GLP-1 drug, to laboratory rats and minipigs with a condition that mimics a subtype of heart failure with preserved ejection fraction that is associated with obesity. They found that while the drug didn't reduce overall body weight, it significantly reduced the heart's stiffness.
The drug also reduced heart enlargement and tissue scarring. The researchers were encouraged to observe that the drug also cleared damaging fat around the heart and liver.
"This opens the door to potentially prescribing GLP-1s at low doses to achieve major cardiovascular protection while minimizing common side effects," said Traci Goodchild, Ph.D., professor of cardiac surgery at the Smidt Heart Institute and co-senior author of the study.
The authors emphasized that the study's findings do not diminish the well-established benefits of weight loss for the heart. Instead, the results indicate that GLP-1 therapy may provide additional, direct cardiovascular benefits independent of weight loss.
"These data suggest that low-dose semaglutide has powerful protective effects on the heart independent of its impact on weight loss," said Mahmoud Elbatreek, Ph.D., a project scientist in the Department of Cardiac Surgery in the Smidt Heart Institute and lead author of the study.
Publication details
Mahmoud H Elbatreek et al., Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction, European Heart Journal (2026). DOI: 10.1093/eurheartj/ehag732
Journal information: European Heart Journal
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Weight loss drugs may protect against heart failure (2026, October 14) retrieved 14 October 2026 from https://medicalxpress.com/news/2026-10-weight-loss-drugs-heart-failure.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com